Industry Developments

BMI View: Of the companies we expected to purchase Mustafa Nevzat Ilac Sanayi (MN Pharmaceuticals), Amgen was the bottom of our list. In terms of synergies and similarities between... 2012-04-26

BMI View: with a few exceptions, the attractiveness of Central And Eastern European (CEE) pharmaceutical markets has remained relatively stable in our Q312 Risk/Reward Ratings (RRRs)... 2012-04-05

BMI View: The European Court of Justice (ECJ)'s ruling on the illegality of a provision of Poland's 2001 law on medicinal products, which had allowed the sale of cheap medicine imports... 2012-04-02

BMI View: Our view that any appointment as Bulgaria's Minister of Health would be under equal pressure as their predecessor to reduce the prices of reimbursed medicines continues to... 2012-04-02

BMI View: The expansion of free medicines coverage for children under the age of three will be welcomed in Belarus. While it is unlikely to significantly boost overall demand for medicines,... 2012-03-27

BMI View: Valeant remains firmly on the acquisition trail and has once again boosted its exposure to Eastern Europe with a particular focus on Russia. BMI's positive view on the attractiveness... 2012-03-27

BMI View: Varichem Pharmaceuticals' success in providing drugs to governments in the Southern African region, as well as unstable markets such as Sudan and Yemen through UNICEF, shows... 2012-03-19

BMI View: Latvia's pharmaceutical market expanded strongly in the first half of 2011 but weaker growth towards the end of the year, combined with ongoing concerns over the external... 2012-03-16

BMI View: Lithuania's drug market is expected to post a gradual recovery over the next five years, but with a short-term worsening economic environment, public and private consumption... 2012-03-15

BMI View: While Greece's revised targets to cut public drug expenditure were included in our forecast scenario in February 2012, the cost-containment legislation that has now been adopted... 2012-03-06